甲硝唑在细菌性阴道病孕妇中的药代动力学
Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis.
作者信息
Wang Xin, Nanovskaya Tatiana N, Zhan Ying, Abdel-Rahman Susan M, Jasek Marlo, Hankins Gary D V, Ahmed Mahmoud S
机构信息
Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, TX 77555-0587, USA.
出版信息
J Matern Fetal Neonatal Med. 2011 Mar;24(3):444-8. doi: 10.3109/14767058.2010.497573. Epub 2010 Jul 7.
OBJECTIVE
The present study was undertaken to investigate the pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis.
METHODS
Twenty patients received metronidazole (Flagyl ®, Pfizer, 235 East 42nd Street, NY, NY 10017) oral dose 500 mg twice a day for 3 consecutive days. Pharmacokinetic analyses of metronidazole were performed after a single oral dose on the morning of day 4.
RESULTS
Although absolute estimates of metronidazole total body exposure were highest in women during early term pregnancy, weight-corrected estimates of exposure maximum plasma drug concentration (C(max)) and the area under the plasma concentration-versus-time curve (AUC(0-12)), along with apparent oral clearance and distribution volume, were not significantly different between women at early, middle, and late stages of pregnancy and were in the range of reported values for nonpregnant patients receiving a similar dose.
CONCLUSIONS
The pharmacokinetic profile of metronidazole did not change at the different time points assessed during pregnancy.
目的
本研究旨在调查甲硝唑在细菌性阴道病孕妇中的药代动力学。
方法
20例患者接受甲硝唑（弗来格 ®，辉瑞公司，纽约州纽约市东42街235号，邮编10017）口服给药，剂量为500毫克，每日两次，连续3天。在第4天早晨单次口服给药后进行甲硝唑的药代动力学分析。
结果
尽管妊娠早期妇女甲硝唑全身暴露的绝对估计值最高，但校正体重后的最大血浆药物浓度（C(max)）和血浆浓度-时间曲线下面积（AUC(0-12)）的暴露估计值，以及表观口服清除率和分布容积，在妊娠早期、中期和晚期妇女之间没有显著差异，且在接受相似剂量的非妊娠患者报告值范围内。
结论
在孕期评估的不同时间点，甲硝唑的药代动力学特征没有变化。
Zotero 插件